Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04484623Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 18
01
Overview
A Phase 3 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Oct 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04484623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484623.